Rhabdomyosarcoma

Oncology·MeSH: Rhabdomyosarcoma

Prevalence

0.5 / 100K

8 drugs in development·4 companies·11 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
actinomycin d	GH Research PLC (GHRS)
Dactinomycin	Merus N.V. (MRUS)
Dactinomycin	Filana Therapeutics Inc. (FLNA)
vincristine	GH Research PLC (GHRS)
Vinorelbine Tartrate	Filana Therapeutics Inc. (FLNA)

Phase 2(1)

Drug	Company
vinorelbine	GH Research PLC (GHRS)

Phase 4(2)

Drug	Company
Dactinomycin	ENANTA PHARMACEUTICALS INC (ENTA)
pharmacotherapy with amiodarone 200 mg per day	GH Research PLC (GHRS)

BioSniper tracks 8 drugs in development for Rhabdomyosarcoma across 4 companies.

There are 11 clinical trials targeting Rhabdomyosarcoma tracked by BioSniper.

The estimated prevalence of Rhabdomyosarcoma is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.